TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction. April 21, 2006